Sinocelltech Ltd.

This phase 3 trial tests whether adding the experimental drug SCTC21C to standard chemotherapy (bortezomib, cyclophosphamide, dexamethasone) works better than chemo alone for people newly diagnosed with AL amyloidosis. The study will enroll 90 participants and measure how well th…

This study tests a new medicine called SCT520FF for people with wet age-related macular degeneration (nAMD), a leading cause of vision loss. About 82 adults aged 45 to 80 will receive the drug to see if it is safe and can help control the disease. The goal is to reduce fluid buil…

This phase 3 trial is testing whether adding an experimental drug called SCTC21C to a standard three-drug regimen (bortezomib, lenalidomide, and dexamethasone) can help people with newly diagnosed multiple myeloma who are not eligible for a stem cell transplant. The study will en…

This study tests an experimental drug called SCT650C in 60 adults with moderate to severe hidradenitis suppurativa (HS), a painful skin condition causing boils and tunnels. The goal is to see if the drug can reduce abscesses and inflammation by at least 75% after 16 weeks. Partic…

This study tests a new drug called SCTB14 against the standard drug pembrolizumab for people with advanced non-small cell lung cancer that has not been treated yet. About 246 adults with a specific tumor marker (TPS ≥10%) will receive either SCTB14 or pembrolizumab to see which o…

This study is testing a new medicine called SCT800 to prevent bleeding episodes in people with severe hemophilia A who have not been treated before. The goal is to see if regular infusions of SCT800 can safely reduce the number of bleeds. About 36 male participants will receive t…